ProQR Therapeutics N.V Book Value Per Share Growth & History (PRQR)
ProQR Therapeutics N.V's book value per share was €0.47 for fiscal 2025.
View full ProQR Therapeutics N.V company overviewProQR Therapeutics N.V annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €0.47 | -€0.37 | −44.33% |
| 2024 | 2024-12-31 | €0.84 | €0.33 | +65.45% |
| 2023 | 2023-12-31 | €0.51 | -€0.32 | −38.69% |
| 2022 | 2022-12-31 | €0.83 | -€0.77 | −48.03% |
| 2021 | 2021-12-31 | €1.60 | €0.54 | +51.40% |
| 2020 | 2020-12-31 | €1.05 | -€0.69 | −39.65% |
| 2019 | 2019-12-31 | €1.75 | -€0.41 | −18.84% |
| 2018 | 2018-12-31 | €2.15 | €1.07 | +99.26% |
| 2017 | 2017-12-31 | €1.08 | -€1.20 | −52.52% |
| 2016 | 2016-12-31 | €2.28 | -€1.57 | −40.84% |
| 2015 | 2015-12-31 | €3.85 | — | — |
ProQR Therapeutics N.V quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €0.56 | -€0.07 | −11.43% |
| Q1 2026 | 2026-03-31 | €0.36 | -€0.39 | −52.38% |
| Q4 2025 | 2025-12-31 | €0.47 | -€0.37 | −44.33% |
| Q3 2025 | 2025-09-30 | €0.54 | €0.24 | +77.13% |
| Q2 2025 | 2025-06-30 | €0.64 | €0.23 | +58.05% |
| Q1 2025 | 2025-03-31 | €0.75 | €0.32 | +75.53% |
| Q4 2024 | 2024-12-31 | €0.84 | €0.33 | +65.45% |
| Q3 2024 | 2024-09-30 | €0.31 | -€0.27 | −46.54% |
| Q2 2024 | 2024-06-30 | €0.40 | -€0.24 | −37.13% |
| Q1 2024 | 2024-03-31 | €0.43 | -€0.30 | −41.48% |
| Q4 2023 | 2023-12-31 | €0.51 | -€0.32 | −38.69% |
| Q3 2023 | 2023-09-30 | €0.57 | -€0.34 | −37.10% |
| Q2 2023 | 2023-06-30 | €0.64 | -€0.58 | −47.74% |
| Q1 2023 | 2023-03-31 | €0.73 | -€0.68 | −48.37% |
| Q4 2022 | 2022-12-31 | €0.83 | -€0.77 | −48.03% |
| Q3 2022 | 2022-09-30 | €0.91 | -€0.97 | −51.73% |
| Q2 2022 | 2022-06-30 | €1.22 | -€0.56 | −31.43% |
| Q1 2022 | 2022-03-31 | €1.41 | — | — |
| Q4 2021 | 2021-12-31 | €1.60 | €0.54 | +51.40% |
| Q3 2021 | 2021-09-30 | €1.88 | €0.52 | +37.66% |
| Q2 2021 | 2021-06-30 | €1.79 | €0.30 | +20.55% |
| Q4 2020 | 2020-12-31 | €1.05 | -€0.69 | −39.65% |
| Q3 2020 | 2020-09-30 | €1.37 | -€0.02 | −1.36% |
| Q2 2020 | 2020-06-30 | €1.48 | -€0.16 | −9.52% |
| Q1 2020 | 2020-03-31 | €1.52 | — | — |
| Q4 2019 | 2019-12-31 | €1.75 | -€0.41 | −18.84% |
| Q3 2019 | 2019-09-30 | €1.39 | — | — |
| Q2 2019 | 2019-06-30 | €1.64 | €1.01 | +160.70% |
| Q4 2018 | 2018-12-31 | €2.15 | €1.07 | +99.26% |
| Q2 2018 | 2018-06-30 | €0.63 | — | — |
| Q4 2017 | 2017-12-31 | €1.08 | -€0.58 | −35.08% |
| Q4 2016 | 2016-12-31 | €1.66 | — | — |
ProQR Therapeutics N.V book value per share trends
Over the last five fiscal years, ProQR Therapeutics N.V's book value per share decreased from €1.05 to €0.47, a change of -€0.59. The latest reported quarter, Q2 2026, shows €0.56.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ProQR Therapeutics N.V source filings ↗